Strongly reduced alloreactivity and long-term survival times of cardiac allografts in Vav1- and Vav1/Vav2-knockout mice

Transplant International

Volumn 20, Issue 4, 2007, Pages 353-364

  Weckbecker, Gisbert ^a   Bruns, Christian ^a   Fischer, Klaus Dieter ^b   Heusser, Christoph ^a   Li, Jianping ^a   Metzler, Barbara ^a   Morris, Randall E ^a   Nuesslein Hildesheim, Barbara ^a   Raulf, Friedrich ^a   Wieczorek, Grazyna ^a   Zenke, Gerhard ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Alloreactivity; Antibody; Graft; Mouse; T cell; Vav

Indexed keywords

2,4 DINITROPHENOL; ALLOANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; UNCLASSIFIED DRUG; VAV 1 PROTEIN; VAV 2 PROTEIN; VAV PROTEIN;

ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL SKIN DISEASE; BAGG ALBINO MOUSE; BLOOD CULTURE; CARDIAC GRAFT REJECTION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; IMMUNE DEFICIENCY; KNOCKOUT MOUSE; LYMPHOCYTE TRANSFER; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECIPIENT; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANIMALS; DINITROPHENOLS; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEMOCYANIN; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-VAV; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33847212511     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00438.x     Document Type: Article

References (43)

1. Bustelo R, Ledbetter JR, Barbacid M. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature 1992; 356: 68.
2. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 2001; 20: 6372.
3. Rossman KL, Der CJ, Sondek J. GEF means go: turning on Rho GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005; 6: 167.
4. Palmby TR, Abe K, Der CJ. Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity. J Biol Chem 2002; 277: 39350.
5. Turner M, Billadeau DD. Vav proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol 2002; 2: 476.
6. Zugaza JL, Lopez-Lago MA, Caloca MJ, Dosil M, Movilla N, Bustelo XR. Structural determinants for the biological activity of Vav proteins. J Biol Chem 2002; 277: 45377.
7. Coso OA, Chiariello M, Yu JC, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81: 1137.
8. Swat W, Fujikawa K. The Vav family: at the crossroads of signaling pathways. Immunol Res 2005; 32: 259.
9. Heo J, Thapar R, Campbell SL. Recognition and activation of Rho GTPases by Vav1 and Vav2 guanine nucleotide exchange factors. Biochemistry 2005; 44: 6573.
10. Margolis B, Hu P, Katzav S, et al. Tyrosine phosphorylation of Vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 1992; 356: 71.
11. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, Bustelo XR. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the Vav proto-oncogene product. Nature 1997; 385: 169.
12. Han J, Das B, Wei W, et al. Lck regulates Vav activation of members of the Rho family of GTPases. Mol Cell Biol 1997; 17: 1346.
13. Tybulewicz VL, Ardouin L, Prisco A, Reynolds LF. Vav1: a key signal transducer downstream of the TCR. Immunol Rev 2003; 192: 42.
14. Tybulewicz VLJ. Vav-family proteins in T-cell signalling. Curr Opin Immunol 2005; 17: 267.
15. Katzav S. Vav1: an oncogene that regulates specific transcriptional activation of T cells. Blood 2004; 103: 2443.
16. Blanchet F, Cardona A, Letimier FA, Hershfield MS, Acuto O. CD28 costimulatory signal induces protein arginine methylation in T cells. J Exp Med 2005; 202: 371.
17. + thymocytes. Nature 1995; 374: 474.
18. Tarakhovsky A, Turner M, Schaal S, et al. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 1995; 374: 467.
19. Holsinger LJ, Graef IA, Swat W, et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr Biol 1998; 8: 563.
20. Costello PS, Walters AE, Mee PJ, et al. Rho-family GTP exchange factor Vav is a critical transducer of T-cell receptor signals to the calcium, ERK, and NF-κ-B pathways. Proc Natl Acad Sci U S A 1999; 96: 3035.
21. Acuto O, Cantrell D. T-cell activation and the cytoskeleton. Annu Rev Immunol 2000; 18: 165.
22. Wulfing C, Bauch A, Crabtree GR, Davis MM. Vav exchange factor is an essential regulator in actin dependent receptor translocation to the lymphocyte-antigen-presenting cell interface. Proc Natl Acad Sci U S A 2000; 97: 10150.
23. Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, Altman A. Vav1/Rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells. J Cell Biol 2001; 155: 331.
24. Reynolds LF, De Bettignies C, Norton T, Beeser A, Chernoff J, Tybulewicz VLJ. Vav1 transduces T-cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J Biol Chem 2004; 279: 18239.
25. Vicente-Manzanares M, Cruz-Adalia A, Martin-Cofreces NB, et al. Control of lymphocyte shape and the chemotactic response by the GTP exchange factor Vav. Blood 2005; 105: 3026.
26. Wells CM, Bhavsar PJ, Evans IR, et al. Vav1 and Vav2 play different roles in macrophage migration and cytoskeletal organization. Exp Cell Res 2005; 310: 303.
27. Billadeau DD, Mackie SM, Schoon RA, Leibson PJ. The Rho family guanine nucleotide exchange factor Vav-2 regulates the development of cell-mediated cytotoxicity. J Exp Med 2000; 192: 381.
28. Tedford K, Nitschke L, Girkontaite I, et al. Compensation between Vav-1 and Vav-2 in B-cell development and antigen receptor signaling. Nat Immunol 2001; 2: 548.
29. Turner M. The role of Vav proteins in B-cell responses. Adv Exp Med Biol 2002; 512: 29.
30. Cella M, Fujikawa K, Tassi I, et al. Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity. J Exp Med 2004; 200: 817.
31. Hebeis B, Vigorito E, Kovesdi D, Turner M. Vav proteins are required for B-lymphocyte responses to LPS. Blood 2005; 106: 635.
32. Paccani SR, Boncristiano M, Patrussi L, et al. Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. Blood 2005; 106: 626.
33. Kurosaki T. Vav: a newcomer in innate receptor signaling. Blood 2005; 106: 389.
34. Saborit-Villarroya I, Del Vale JM, Romero X, et al. The adaptor protein 3BP2 binds human CD244 and links this receptor to vav signaling, ERK activation, and NK cell killing. J Immunol 2005; 175: 4226.
35. Tanaka Y, So T, Lebedeva S, Croft M, Altman A. Impaired IL-4 and c-Maf expression and enhanced Th1-cell development in Vav1-deficient mice. Blood 2005; 106: 1286.
36. Fischer KD, Kong YY, Nishina H, et al. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr Biol 1998; 8: 554.
37. Corry RJ, Winn HJ, Russel PS. Primarily vascularized allografts of hearts in mice. Transplantation 1973; 16: 343.
38. Sarris GE, Mitchell RS, Billigham ME, Glasson JR, Cahill PD, Miller DC. Inhibition of accelerated cardiac allograft arteriosclerosis by fish oil. J Thorac Cardiovasc Surg 1989; 97: 841.
39. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signaling. Nat Rev Immunol 2003; 3: 939.
40. Zakaria S, Gomez TS, Savoy DN, et al. Differential regulation of TCR-mediated gene transcription by Vav family members. J Exp Med 2004; 199: 429.
41. Martinez Gakidis MA, Cullere X, Olson T, et al. Vav GEFs are required for beta2 integrin-dependent functions of neutrophils. J Cell Biol 2004; 166: 273.
42. Fujikawa K, Miletic AV, Alt FW, et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cell. J Exp Med 2003; 198: 1595.
43. + T cells. Immunity 2005; 23: 263.